China Needs To Align With International Standards To Grow Its Biologics Industry: BIO
This article was originally published in The Pink Sheet Daily
On the plus side, China has pledged policy support and hefty funding to build up its biologics industry. However, weak intellectual property protection, a challenging regulatory environment and market access and profitability issues still deter industry investment, according to the Biotechnology Industry Organization.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.